Effectiveness of IL-23 Inhibitor Guselkumab in Real-World Chinese Patients with Psoriasis During a 20-Week Period

Figures & data

Table 1 Baseline Patients’ Characteristics (N=68)

Gender	n (%)
Male	56 (82.3)
Age	Years
Mean (SD)	41.2 (12.4)
Median	41.0
Range	18–77
Body weight	kg
Mean (SD)	76.3 (13.6)
Median	76.0
Range	48.0–117.8
Previous systemic medication	n (%)
Previous use of Systemic conventional oral medication^+	19 (27.9)
Methotrexate	12 (17.6)
Acitretin	8 (11.8)
Cyclosporin	3 (4.4)
History of phototherapy	4 (5.9)
Previous use of traditional Chinese medicine	16 (23.5)
Previous biologics^+	n (%)
TNF inhibitors	4 (5.9)
IL-12/23 inhibitor (ustekinumab)	4 (5.9)
IL-17 inhibitors	18 (26.5)
Secukinumab	17 (25.0)
Ixekizumab	5 (7.4)

Note: ⁺Previous medication may be more than one agent in each patient.

Abbreviations: SD, standard deviation; TNF, tumor necrosis factor; IL, interleukin.

Table 2 Reasons for Switching Biologics from Previous Biologics

Reasons	n(%)
Primary inefficacy	10 (45.5)
Loss of efficacy	11 (50)
Adverse events	1 (4.5)
Total	22 (100)

Abbreviation: n, number of patients.

Figure 1 Mean PASI scores (± SD) at different time points for all patients and patients stratified by prior biologic use. *All Ps=0.000 versus Week 0 for all groups, respectively.

Table 3 Subgroup Analysis for PASI Response at Week 4, Week 12 and Week 20

Subgroup	Time	PASI 90	P value	PASI 100	P value	PASI Score <3	P value
Female	Week 4	0%	1.000	0%	1.000	8.3%	0.549
Male		3.6%		3.6%		5.4%
Female	Week 12	25%	0.742	16.7%	1.000	58.3%	0.752
Male		32.1%		21.4%		48.2%
Female	Week 20	83.3%	0.487	58.3%	0.527	75.0%	1.000
Male		69.6%		44.6%		76.8%
Body weight ≤75 kg	Week 4	6.1%	0.232	6.1%	0.232	12.1%	0.050
Body weight >75 kg		0%		0%		0%
Body weight ≤75 kg	Week 12	39.4%	0.191	24.2%	0.555	57.6%	0.332
		22.9%		17.1%		42.9%
Body weight >75 kg
Body weight ≤75 kg	Week 20	72.7%	1.000	51.5%	0.627	75.8%	1.000
Body weight >75 kg		71.4%		42.9%		77.1%
No previous biologics	Week 4	2.2%	0.546	2.2%	0.546	6.5%	1.000
						4.5%
With previous biologics		4.5%		4.5%
No previous biologics	Week 12	41.3%	0.010	28.3%	0.027	63.0%	0.004
With previous biologics		9.1%		4.5%		22.7%
No previous biologics	Week 20	80.4%	0.042	58.7%	0.009	89.1%	0.001
With previous biologics		54.5%		22.7%		50.0%

Abbreviation: PASI, psoriasis area and severity index.